1. Home
  2. VALN vs BVS Comparison

VALN vs BVS Comparison

Compare VALN & BVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VALN
  • BVS
  • Stock Information
  • Founded
  • VALN 2012
  • BVS 2011
  • Country
  • VALN France
  • BVS United States
  • Employees
  • VALN N/A
  • BVS N/A
  • Industry
  • VALN Biotechnology: Biological Products (No Diagnostic Substances)
  • BVS Biotechnology: Electromedical & Electrotherapeutic Apparatus
  • Sector
  • VALN Health Care
  • BVS Health Care
  • Exchange
  • VALN Nasdaq
  • BVS Nasdaq
  • Market Cap
  • VALN 595.2M
  • BVS 656.3M
  • IPO Year
  • VALN 2021
  • BVS 2021
  • Fundamental
  • Price
  • VALN $7.44
  • BVS $10.01
  • Analyst Decision
  • VALN Strong Buy
  • BVS Strong Buy
  • Analyst Count
  • VALN 2
  • BVS 3
  • Target Price
  • VALN $17.00
  • BVS $15.00
  • AVG Volume (30 Days)
  • VALN 81.7K
  • BVS 229.0K
  • Earning Date
  • VALN 03-20-2025
  • BVS 03-11-2025
  • Dividend Yield
  • VALN N/A
  • BVS N/A
  • EPS Growth
  • VALN N/A
  • BVS N/A
  • EPS
  • VALN N/A
  • BVS N/A
  • Revenue
  • VALN $176,817,979.00
  • BVS $555,061,000.00
  • Revenue This Year
  • VALN $22.73
  • BVS $11.37
  • Revenue Next Year
  • VALN $11.39
  • BVS N/A
  • P/E Ratio
  • VALN N/A
  • BVS N/A
  • Revenue Growth
  • VALN N/A
  • BVS 10.40
  • 52 Week Low
  • VALN $3.62
  • BVS $3.90
  • 52 Week High
  • VALN $9.50
  • BVS $14.38
  • Technical
  • Relative Strength Index (RSI)
  • VALN 60.56
  • BVS 41.73
  • Support Level
  • VALN $6.62
  • BVS $9.74
  • Resistance Level
  • VALN $8.42
  • BVS $10.61
  • Average True Range (ATR)
  • VALN 0.46
  • BVS 0.36
  • MACD
  • VALN 0.05
  • BVS -0.06
  • Stochastic Oscillator
  • VALN 69.85
  • BVS 19.09

About VALN Valneva SE

Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates the majority of its revenue from product sales.

About BVS Bioventus Inc.

Bioventus Inc is a medical technology company. The company is engaged in developing and commercializing clinically differentiated treatments that engage and enhance the body's natural healing process. It offers a diverse portfolio of products to serve physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine and neurosurgery. Its portfolio of products is grouped into three verticals based on clinical use: Pain Treatments, Surgical Solutions, and Restorative Therapies. Geographical presence is in the United States which derives key revenue, and International markets.

Share on Social Networks: